Correlation of Drug Response with the ATP Tumorchemosensitivity Assay in Primary FIGO Stage III Ovarian Cancer
- 31 May 2000
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 77 (2) , 258-263
- https://doi.org/10.1006/gyno.2000.5728
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- “Recurrence within 6 Months of Platinum Therapy”: An Adequate Definition of “Platinum-Refractory” Ovarian Cancer?Gynecologic Oncology, 1998
- Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancerAnti-Cancer Drugs, 1998
- Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivityAnti-Cancer Drugs, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Chemosensitivity testing in ovarian cancerCancer, 1993
- Prediction of Response to Drug Therapy of CancerDrugs, 1992
- Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.Journal of Clinical Oncology, 1989
- Application of an ATP-bioluminescence assay in human tumor chemosensitivity testingGynecologic Oncology, 1988
- Pharmacokinetics of adriamycin in patients with breast cancer: Correlation between pharmacokinetic parameters and clinical short-term responseEuropean Journal of Cancer and Clinical Oncology, 1982
- Kinetics of cis‐dichlorodiammineplatinumClinical Pharmacology & Therapeutics, 1979